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Abstract
Background: Dendritic cells (DCs) mount tumor-associated antigens (TAAs), and the double-stranded RNA adjuvant
Poly(I:C) stimulates Toll-like receptor 3 (TLR3) signal in DC, which in turn induces type I interferon (IFN) and
interleukin-12 (IL-12), then cross-primes cytotoxic T lymphocytes (CTLs). Proliferation of CTLs correlates with tumor
regression. How these potent cells expand with high quality is crucial to the outcome of CTL therapy. However,
good markers reflecting the efficacy of DC-target immunotherapy have not been addressed.
Methods: Using an EG7 (ovalbumin, OVA-positive) tumor-implant mouse model, we examined what is a good
marker for active CTL induction in treatment with Poly(I:C)/OVA.
Results: Simultaneous administration of Poly(I:C) and antigen (Ag) OVA significantly increased a minor population of
CD8+ T cells, that express CD11c in lymphoid and tumor sites. The numbers of the CD11c+ CD8+ T cells correlated with
those of induced Ag-specific CD8+ T cells and tumor regression. The CD11c+ CD8+ T cell moiety was characterized by
its high killing activity and IFN-γ-producing ability, which represent an active phenotype of the effector CTLs. Not only
a TLR3-specific (TICAM-1-dependent) signal but also TLR2 (MyD88) signal in DC triggered the expansion of CD11c+
CD8+ T cells in tumor-bearing mice. Notably, human CD11c+ CD8+ T cells also proliferated in peripheral blood
mononuclear cells (PBMC) stimulated with cytomegalovirus (CMV) Ag.
Conclusions: CD11c expression in CD8+ T cells reflects anti-tumor CTL activity and would be a marker for
immunotherapeutic efficacy in mouse models and probably cancer patients as well.
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Background
Efficient induction of active CTLs is important for suc-
cessful anti-tumor immunotherapy [1]. Poly(I:C), which
is an adjuvant recognized by the pattern-recognition re-
ceptors (PRR) TLR3 and Melanoma differentiation-
associated gene 5 (MDA5), acts on DCs to evoke potent
CTL proliferation followed by tumor regression [2, 3].
There are three important steps for successful CTL-
dependent tumor eradication: (i) CD8+ T cell priming in
lymphoid organs; (ii) CTL infiltration into tumor sites;
and (iii) keeping CTLs tumoricidal in tumor microenvir-
onment. The first step, TAA and Poly(I:C) cross-prime
Ag-specific CD8+ T cells by cross-presentation in DCs
[4], which leads to CTL-dependent tumor regression
[5, 6]. Poly(I:C) adjuvant accomplishes DCs matur-
ation and the cross-presentation of exogenous Ags
[7]. Poly(I:C) may also promote the second and third
steps by acting on myeloid or stromal cells in lymph
nodes and tumor.
Poly(I:C) facilitates the maturation of DCs and
optimizes the Ag-presentation that culminates in the
cross-presentation process. Additionally, Poly(I:C) up-
regulates the expression of positive co-stimulatory mole-
cules and the production of cytokines in mature DCs.
The maturation of DC is also known to prime CD8+ T
cells [7]. The second step concerns the migration of
primed-CTLs to the tumor sites. Activated CD8+ T cells
up-regulate expression of chemokine receptors such as
CXCR3 and they are attracted to tumor sites expressing
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CXCR3 ligands such as CXCL9, CXCL10 and CXCL11
[8]. The third step concerns direct killing of tumor cells
in the tumor sites. Tumors with poor prognosis fre-
quently express the Programmed death-ligand 1 (PD-L1)
protein, and this PD-L1-high environment inhibits CTL
killing activity via the PD-L1/PD-1 signaling pathway
[9, 10]. In mouse tumor models, the degree of tumor
regression positively correlates with the expansion of
tumor Ag-specific CD8+ T cells and the level of intra-
tumor CD8+ T cells. These parameters are in turn in-
fluenced by the quality of DC maturation [9]. However, it
is difficult to assess the therapeutic efficacy in anti-tumor
immunotherapy by measuring such parameters in human
cancer patients. Therefore, it is anticipated to search for
simple markers measurable with patients’ blood that re-
flect the degrees of expansion and activation of Ag-
specific CTLs.
In this study, we treated EG7 tumor-implant mice with
OVA Ag and Poly(I:C): EG7 is an OVA-expressing
tumor cell line, and able to assess TAA-specific CD8+
T cells by tetramer assay. We found that the activated
CD8+ T cells expressed the CD11c molecule, and that
most of the tumor-infiltrating CD8+ T cells were
CD11c-positive in OVA and Poly(I:C)-treated mice.
The up-regulation of CD11c expression on CD8+ T
cells was evoked by various immunological stimuli,
such as microbial infections or Ag and agonistic anti-
4-1BB monoclonal antibody [11]. CD8+ T cells do not
always have a uniform phenotype in terms of surface
markers and functions. A bipolar immunological pheno-
type has been reported on the CD11c+ CD8+ T cell moi-
eties: an effector function contributing to the elimination
of pathogenic microbes and, controversially, a suppressive
function reducing immune response [11].
Here we found that the Ag + Poly(I:C)-induced
CD11c+ CD8+ T cells had an anti-tumor effector
phenotype. We also observed that the degree of CD11c
expression in intratumor CD8+ T cells paralleled their
level of activation. The Ag-induced expansion of
CD11c+ CD8+ T cells was also observed in human
PBMCs. The level of CD11c expression in CD8+ T cells
can be a useful marker for evaluation of the degree of
expansion and the quality of tumor-specific CTLs as




Wild-type C57BL/6 J mice were purchased from CLEA.
Ticam1−/− and Mavs−/− mice were made in our labora-
tory. OT-1 mice were kindly provided by N. Ishii
(Tohoku University, Miyagi, Japan). All mice were back-
crossed >8 times to C57BL/6 background and main-
tained under specific pathogen-free condition in the
animal faculty of the Hokkaido University Graduate
School of Medicine. Animal experiments were performed
according to the guidelines set by the animal safety center,
Hokkaido University, Japan.
Cell culture, reagents and antibodies
EL4 and EG7 cells were purchased from ATCC (VA,
USA). WT1-C1498 cells were kindly provided by H.
Sugiyama (Osaka University, Osaka, Japan) [12]. EL4
cells were cultured in RPMI 1640 (GIBCO, the catalog
number: 11875-093, CA, USA) supplemented with
10 % heat-inactivated FBS (Thermo Fisher Scientific,
SH30910.03, MA, USA) and 50 IU penicillin/50 μg/ml
streptomycin (GIBCO, 15070-063). EG7 cells were
cultured in RPMI 1640 supplemented with 10 % heat-
inactivated FBS, 55 μM 2-mercaptoethanol (GIBCO,
21985-023), 10 mM HEPES (GIBCO, 15630-080), 1 mM
sodium pyruvate (GIBCO, 11360-070), 50 IU penicillin/
50 μg/ml streptomycin and 0.5 mg/ml G418 (Roche, 04
727 894 001, Basel, Schweiz). WT1-C1498 cells were
cultured in RPMI 1640 supplemented with 10 %
heat-inactivated FBS, 55 μM 2-mercaptoethanol, 50 IU
penicillin/50 μg/ml streptomycin and 0.5 mg/ml G418.
Poly(I:C) and MALP (macrophage-activating lipopro-
tein)-2 s were purchased from GE healthcare Life
Sciences (the catalog number: 27-4732-01, IL, USA)
and Biologica (Aichi, Japan), respectively. EndogGade®
Ovalbumin (EndoOVA) was purchased from Hyglos
(321001, Bayern, Germany). OVA257-264 peptide
(SIINFEKL: SL8), OVA (H2Kb-SL8) Tetramer, WT1
(H-2Db-Db126) Tetramer, HLA-A*02:01 CMV pp65
Tetramer-NLVPMVATV-PE and HLA-A*24:02 CMV
pp65 Tetramer-QYDPVAALF-PE were purchased from
MBL (TS-5001-P, TS-5001-1, TS-M504-1, TS-0010-1C,
TS-0020-1C, Aichi, Japan).
The following antibodies, anti-mouse CD3 (Clone:
145-2C11, the catalog number: 100306 and 100308),
anti-mouse CD8α (53–6.7, 100729), anti-mouse CD11c
(N418, 117317), anti-mouse CD16/32 (93, 101302),
anti-mouse CD62L (MEL-14, 104405), anti-mouse
CD103 (2E7, 121405), anti-mouse IFN-γ (XMG1.2,
505809), anti-mouse IL-2 (JES6-5H4), anti-mouse
TNF-α (MP6-XT22, 506303), anti-human CD3 (HIT3a,
300317) and anti-human CD11c (3.9, 301613) were
purchased from BioLegend (CA, USA). Anti-human
CD8 (T8) was from BECKMAN COULTER (6603861,
CA, USA).
Human FcR Blocking Reagent and CMV pp65-
Recombinant Protein human Cytomegalovirus were
purchased from Miltenyi Biotec (130-059-901, 130-
091-824, Nordrhein-Westfalen, Germany). ViaProbe
was purchased from BD Biosciences (555816, CA,
USA). Chromium-51 Radionuclide was purchased from
PerkinElmer (NEZ030S001MC, MA, USA).
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Reverse transcription-PCR and real-time PCR
In most samples, total RNA was prepared using TRI-
zol Reagent (Ambion, 15596018, TX, USA). Reverse
transcription-PCR was carried out using a High
Capacity cDNA Reverse Transcription kit (Applied
Biosystems, 4368814, MA, USA). For total RNA puri-
fication from OVA-tetramer+ CD8+ T cells, CellAmp®
Whole Transcriptome Amplification Kit (Real Time)
Ver.2 (Takara, 3734, Shiga, Japan) was used according
to the manufacturer’s instructions. Real-time PCR was
performed using a Step One real-time PCR system
(Applied Biosystems, 4368813). Sequences of primers
in this study are shown in Additional file 1: Table S1.
Levels of target mRNAs were normalized to Gapdh
and fold-induction of transcripts was calculated using
the ddCT method.
Tumor challenge and adjuvant therapy
Mice were shaved at the back and subcutaneously
injected with 200 μl of 2 × 106 EG7 cells or 0.6 × 106
WT1-C1498 cells in PBS. Tumor volume was calculated
by using the formula: Tumor volume [mm3] = 0.52 × (long
diameter [mm]) × (short diameter [mm]) 2. In the EG7
tumor bearing model, 100 μg of OVA with or without ad-
juvant (50 μg of Poly(I:C) or 50 nmol of MALP2s) was s.c.
injected around tumor when the tumor volume reached
about 200–600 mm3. OVA and adjuvant treatment was
conducted once or twice at weekly intervals. 6 or 7 days
after the last treatment, spleens, inguinal lymph nodes and
tumor tissues were harvested for analysis. For measuring
of intracellular IFN- γ, TNF-α and IL-2 staining, har-
vested cells were pulsed with 100 nM of SL8 for 6 h,
and 10 μg/ml of Blefeldin A (Sigma-Aldrich, B7651-
5MG, MO, USA) was added to the cells during the
last 4 h. In WT1-C1498 tumor bearing model, PBS or
50 μg of Poly(I:C) was s.c. injected around tumor at
day 5 and 12 after tumor implantation.
Analysis of tumor-infiltrating lymphocytes
EG7 or WT1-C1498 tumors were excised from the tumor
bearing mice. Isolated tumor was cut finely and treated
with 0.05 mg/ml collagenase I (Sigma-Aldrich, C0130-
100MG), 0.05 mg/ml collagenase IV (Sigma-Aldrich,
C5138-1G), 0.025 mg/ml hyaluronidase (Sigma-Aldrich,
H6254-500MG) and 0.01 mg/ml DNase I (Roche, 10 104
159 001) in Hank’s Balanced Salt Solution (Sigma-Aldrich,
H9269-500ML) at 33 °C for 15 min. Tumor-infiltrating
CD8+ T cells were analyzed and sorted on FACS AriaII
(BD Biosciences).
OT-1 proliferation assay
OT-1 T cells were prepared from spleens of OT-1 mice
by CD8-microbeads (Miltenyi Biotec, 130-049-401).
CD11c+ cells were isolated from spleens of wild-type
mice by CD11c-microbeads (Miltenyi Biotec, 130-052-
001). OT-1 T cells were labeled with 1 μM of CFSE for
10 min at 37 °C. 1 × 105 CD11c+ cells and 2 × 104 OT-
1 T cells were co-cultured in 200 μl of medium with
4 μg/ml of OVA or OVA + 50 μg/ml of Poly(I:C) in 96-
well flat bottom plate. After 60 h, these cells were
stained with anti-CD8α, anti-CD3, and anti-CD11c. OT-
1 T cell proliferation was determined with diminution of
CFSE on FACS AriaII.
Cytotoxic assay of CD8+ T cells
EG7 tumor bearing mice were challenged with OVA or
OVA + Poly(I:C) on day 9 after tumor implantation. At
day 15, CD8+ T cells were isolated from splenocytes by
FACS sorting. EG7 and EL4 cells were labeled with 51Cr
for 90 min and then washed three times with medium.
CD8+ T cells (effecter cells) and 51Cr-labeled EG7 or
EL4 (target cells) were co-cultured at the indicated ratio.
After 4 h, supernatants were harvested and 51Cr release
was measured in each sample. Specific lysis was calculated
by using the formula: Cytotoxicity (%) = [(experimental
release-spontaneous release) / (total release-spontaneous
release)] × 100.
Ex vivo CMV-specific CD8+ T cell immunization and HLA
CMV tetramer assay
Human PBMCs were isolated from healthy donors by
Ficoll-Paque PLUS (GE Healthcare Life sciences,
17-1440-02) following the manufacturer’s protocol.
Haplotypes of donor’s HLA-A allele were checked by
RapiType HLA-A for East Asian Pop (MBL, 4901). The
donors’ HLA-A haplotypes included A*02 or A*24.
The PBMCs were incubated with CMV pp65 protein in
the presence or absence of 20 μg/ml of Poly(I:C) in
RPMI 1640 medium supplemented with 5 % self
plasma, 55 μM 2-mercaptoethanol, and 50 IU penicil-
lin/50 μg/ml streptomycin. On day 2, equal volume of
medium containing recombinant human IL-2 (Pepro
Tech, AF-200-02-50UG, NJ, USA) was added to the
culture dish. The final concentration of IL-2 was 50
U/ml. Two days later, the half volume of medium was
changed to fresh medium containing IL-2 twice a week.
After more than 8 days incubation, we analyzed the pro-
portions of HLA CMV pp65-tetramer+ CD8+ T cells and
CD11c+ CD8+ T cells on FACS AriaII.
Statistical analysis
P-values were calculated with Kluskal-Wallis test with
Dunn’s multiple comparison test or the Student’s
t-test. Error bar represent the SD or SEM between
samples.
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Results
Antigen + Poly(I:C) induces the proliferation of CD11c+
CD8+ T cells in lymphoid tissue
EG7 is an OVA-expressing lymphoma cell line (OVA
positive-EL4 cell line) derived from the C57BL/6 mouse
strain. The EG7 tumor is susceptible to CTL-mediated
cytotoxicity and strongly suppressed by OVA and
Poly(I:C) therapy [2]. We implanted EG7 in the back of
C57BL/6 mice and administered OVA Ag alone or
OVA + Poly(I:C) subcutaneously (s.c.) on day 9 after
tumor implantation. The combination use of Poly(I:C)
and OVA induced tumor regression in mice, whereas
OVA alone treatment had only a minimal effect (Fig. 1a).
On day 15, we harvested spleens and draining lymph
nodes (DLN). The proportion of OVA-specific CD8+ T
cells and CD11c+ CD8+ T cells were then analyzed
(Fig. 1b). In both the spleen and DLN, OVA-specific CD8+
T cells and CD11c+ CD8+ T cells were increased in re-
sponse to Poly(I:C) (Fig. 1c, d). Similar results were ob-
tained with a non-tumor bearing model (Additional file 2:
Figure S1a), thus CD11c+ population expanding as a result
of the proliferation of OVA-specific CD8+ T cells in mice
with OVA+ Poly(I:C). The results indicate that CD11c+
CD8+ T cells contain the Ag-specific CD8+ T cells induced
by Poly(I:C).
Poly(I:C)-stimulated CD11c+ CD8+ T cells have a strong
effector function
We next assessed the phenotype of CD11c+ CD8+ T
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Fig. 1 Antigen and Poly(I:C) administration increases the ratio of CD11c+ CD8+ T cells. a EG7 tumor was implanted to wild-type mice (C57BL/6 J),
and OVA or OVA+ Poly(I:C) was injected around tumor at day 9 after tumor implantation. Tumor volume was measured every 2 to 3 days. b–d 6 days
after OVA administration, the proportions of OVA-specific CD8+ T cells and CD11c+ CD8+ T cells were evaluated on flow cytometer. In panel b, the
gating strategy is shown. The proportions of each cell populations in spleen (c) and DLN (d) are calculated. Error bars show ± SEM; n = 4
to 5 per group. Student’s t-test was performed to analyze statistical significance. * p <0.05. The results are the representatives of three
independent experiments
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and a melanoma tumor-bearing model [15], the CD11c+
CD8+ T cell population reportedly expresses high IFN-γ-
producing ability. In the EG7-bearing model, Poly(I:C)
administration induced IFN-γ production by CD8+ T
cells in the spleen and DLN (left in Fig. 2a). Within
the Poly(I:C)-stimulated CD8+ T cell populations the
CD11c+ population showed a higher ratio of IFN- γ+
cells compared to the CD11c- population (right in
Fig. 2a). Similar results were obtained with cells from
a non-tumor bearing mouse model (Additional file 2:
Figure S1b).
Next, we measured the cytotoxic potential of the
Poly(I:C)-stimulated CD11c+ CD8+ T cells in the spleen.
Total CD8+ T cells and the CD11c- and CD11c+ popula-
tions were isolated from the spleens of OVA + Poly(I:C)-
treated EG7-tumor bearing mice and co-cultured with
51Cr-labeled EG7 or EL4 cells. EL4 represents the
basal cell line with no OVA Ag. The level of CD8+ T
cell-induced cytotoxicity was measured using a 51Cr-
release assay. Total CD8+ T cells isolated from mice
which had been treated with OVA alone were the
negative control. Poly(I:C)-stimulated CD11c+ cells
showed markedly higher cytotoxicity towards EG7
cells (top in Fig. 2b) and EL4 cells (bottom in Fig. 2b)
compared with other groups. Similar results were ob-
served with the OVA + Poly(I:C)-immunized non-
tumor bearing model (Additional file 2: Figure S1c).
Hence in this model, the OVA + Poly(I:C)-stimulated
CD11c+ population attacked mainly OVA-positive EG7
cells and reactively OVA-negative EL4 cells. These results
indicate that the Poly(I:C)-stimulated CD11c+ cells exerts
OVA-specific, as well as weak by-standing cytotoxicity to-
ward basal EL4 Ag.
Microarray analysis with CD11c+ CD8+ T cells in-
creased in malaria parasite vaccination exhibits the dif-
ferential gene-inducing program compared to CD11c−
CD8+ T cells [14]. Therefore, we analyzed the gene ex-
pression profiles of CD11c− and CD11c+ populations
isolated from the spleens of tumor-bearing mice in the
presence or absence of Poly(I:C) stimulation (Fig. 2c).
Genes such as Ifng, Gzmb (which indicate the CTL ef-
fector function) and Il12r, were highly expressed in the
CD11c+ population compared to the CD11c− population
in both OVA alone and OVA + Poly(I:C) groups. Cxcr3,
which is a chemokine receptor involved in T cell migra-
tion, was also higher in the CD11c+ cells. Although
CD11c+ cells showed high effector gene expression pat-
terns, Pdcd1 (PD1 gene) and Il10 expression was also
high. When comparing the group treated with OVA alone
to that treated with OVA+ Poly(I:C), the expression levels
of Ifng, Gzmb and Pdcd1 in the CD11c+ cells were up-
regulated in response to Poly(I:C) stimulation.
Subsequently, we checked the expression of other mol-
ecules which have been reported as the activated- and
effector-CTL markers (Additional file 3: Figure S2). The
down-regulation of CD62L is one of the effector markers
for CD8+ T cells [16] and the splenic CD11c+ CD8+ T
cells showed higher ratio of CD62L− phenotype than
CD11c− cells. PD-1 expression was consistent with the
gene (Pdcd1) expression. In Malaria infection-mouse
models, CD11c+ CD8+ T cells showed a KLRG+ CD127−
pattern, which is known as a marker of short-lived ef-
fector cells [14]. In the present EG7-bearing models,
CD11+ populations showed a similar pattern. Since
the high IFN-γ-producing ability and anti-tumor abil-
ity of CD103+ CD8+ T cells were reported [17, 18],
we checked the levels of CD103 expression. However,
no positive correlation between CD11c and CD103
expression on CD8+ T cells was observed (Additional
file 3: Figure S2a). The TNF-α and IL-2-producing
ability of CD11c+ population was much higher than
CD11c- population (Additional file 3: Figure S2b). We
further analyzed the gene expression pattern in splenic
CD11c+ and CD11c− populations (top in Additional file 3:
Figure S2c). CD11c+ cells showed higher Klrg1 expression
than CD11c− cells, and the expression level was fur-
ther increased by Poly(I:C)-stimulation. Cd127 and
Cd103 expression levels were lower in CD11c+ cells
than CD11c− cells in both of OVA and OVA+ Poly(I:C)
groups. We additionally checked the markers of CD8+
Tregs: Tgfb and Cd122 [19], and CD11c+ cells only mod-
estly expressed these genes. Thus, the CD11c+ expression
represents a short-lived effector phenotype of CD8+ T
cells.
Intratumor antigen-specific CD11c+ CD8+ T cells
demonstrate the effector phenotype
The infiltration of CTL into tumor and maintenance of
their cytotoxicity are crucial for successful anti-tumor
immunotherapy [9, 20]. Then, we assessed the properties
of intratumor CD8+ T cell populations. First, we mea-
sured the proportions of intratumor OVA-specific CD8+
T cells and CD11c+ CD8+ T cells in tumor of EG7-
bearing mice treated with OVA alone and OVA +
Poly(I:C). The expansion of intratumor OVA-specific
CD8+ T cells was strongly induced following OVA +
Poly(I:C) administration (left in Fig. 3a). Approximately
70 % of intratumor CD8+ T cells expressed the CD11c
molecule even in the absence of Poly(I:C) stimulation,
and the ratio was further increased in the CD11c +
population by Poly(I:C) (right in Fig. 3a). In addition to
the expansion of the CD11c+ moiety, Poly(I:C) up-
regulated the expression level of CD11c on the CD11c+
T cell population (Fig. 3b).
In the OVA + Poly(I:C) group we focused on two
representative mice with different responses: one
with a high degree of tumor regression (the tumor
volume at day 12 was ≤ 200 mm3) and the other with
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a moderate degree of regression (the tumor volume
at day 12 was ≥ 200 mm3) (Additional file 4: Figure
S3a). The ratios of intratumor OVA-specific and
CD11c+ populations in CD8+ T cells were markedly
high in the mice with mild-regressing tumor, but
low in the mice with fast-regressing tumor (Additional
file 4: Figure S3b). Hence, OVA-specific CD11c+ CD8+ T
cells are efficiently expanded and enter into the tumor
during tumor regression and then disappear prior to
remission.
Next, we assessed the parallelism between the CD11c
expression level and the ratio of OVA-specific T cells.
They appeared to be positively correlated (Fig. 3c);
hence, we separated CD11c− , CD11clo-mid and CD11chi
subpopulations from tumor tissue and analyzed their
markers. The expression levels of Ifng, Gzmb, Il10
and Il12rb2 were higher on the CD11chi than the
CD11clo-mid subpopulation in the OVA + Poly(I:C)
group (Fig. 3d). These results indicate that the degree
of CD11c expression in intratumor CD8+ T cells re-
flects the intense activation of Ag-specific CD8+ T
cells. The gene expression patterns between CD11c−
and CD11c+ populations in OVA-specific CD8+ T
cells showed that the levels of Ifng, Gzmb, Prf1 and
Pdcd1 were higher in the OVA-tetramer+ CD11c+
cells than in OVA-tetramer+ CD11c− cells (Fig. 3e).
The expression pattern of other genes: Cd127, Klrg1,
Cd103, Tgfb2 and Cd122, in intratumor CD11c− and
CD11c+ cells was almost consistent with those in
splenic CD11c− and CD11c+ CD8+ T cells (Additional
file 3: Figure S2c). We further assessed the gene ex-
pression levels of exhaustion markers such as Tim3
and Lag3 in intratumor CD11c− and CD11c+ CD8+ T
cells [10]. Tim3 expression levels of intratumor CD11c−
and CD11c+ cells were very low and Lag3 expression was
unchanged by Poly(I:C) stimulation in both CD11c− and
CD11c+ cells (Additional file 3: Figure S2c). These results
indicate that intratumor CD11c+ CD8+ T cells are
non-exhausted/short-lived effector CD8+ T cells. Pos-
sibly, up-regulation of the CD11c and activation of
CD8+ T cells may coincidentally occurs in response
to Poly(I:C) at the CD8+ T cell-priming stage.
The level of CD11c expression correlates with the degree
of Ag-specific cell division
To validate the above hypothesis, an in vitro OT-1 pro-
liferation assay was performed. CFSE-labeled OT-1 cells
were co-cultured with CD11c+ DCs in the presence of
OVA, with or without Poly(I:C) stimulation. Sixty hours
after co-culture the correlation between the number of
cell divisions and the ratio of different OT-1 CD11+ cells
was assessed by FACS gating (Fig. 4a). The rate of OT-1
proliferation and proportion of CD11c+ cells was in-
creased by Poly(I:C) stimulation (left and middle in
Fig. 4b). Furthermore, the proportion of CD11c+ cells
gradually increased in proportion to the number of cell
division, and almost all cells that divided more than
three times were CD11c-positive (right in Fig. 4b). The
CD11c expression was highly induced in the Poly(I:C)
group, but this stimulation was just additive in this in
vitro model. The results indicate that if the priming
signal of CD8+ T cell is sufficiently robust, no specific
second stimulation is mandatory to induce CD11c+ ex-
pression; similar results were obtained using an in vivo
tetramer assay (Fig. 5). In this assay, Ticam1, Mavs and
Ticam1/Mavs knockout mice were immunized with
OVA + Poly(I:C) and the ratios of OVA-specific CD8+ T
cells and CD11c+ CD8+ T cells were measured. The level
of induction of CD11c+ cells paralleled the number of
OVA-specific CD8+ T cells (Fig. 5).
We next confirmed this using another adjuvant.
Wild-type mice were immunized with OVA +MALP2s
[21], which is a TLR2 agonist that induces DC matur-
ation using a different mechanism from Poly(I:C)
(Additional file 5: Figure S4, exact differences will be
shown elsewhere). Like OVA + Poly(I:C), OVA +
MALP2s therapy also induced EG7 tumor regression
(Additional file 5: Figure S4a). Further analysis re-
vealed that MALP2s up-regulated the proportion of
OVA-specific CD8+ and CD11c+ CD8+ T cells, as with
Poly(I:C) treatment (Additional file 5: Figure S4b).
Hence, it is likely that the occurrence of the CD11c+
population relies not only on the TICAM-1 pathway
but the MyD88 pathway which up-regulate the cross-
presentation.
(See figure on previous page.)
Fig. 2 CD11c+ CD8+ T cells show anti-tumor phenotypes in response to Poly(I:C). a Mice loaded with EG7 tumor were treated with OVA
or OVA + Poly(I:C) at day 9. Six days later, spleens and DLN were harvested and the proportions of IFN-γ+ CD8+ T cells were evaluated
on flow cytometer. b CD11c− CD8+ T cells and CD11c+ CD8+ T cells were isolated from splenocytes by FACS sorting at day 15. Isolated
cells were co-cultured with 51Cr-laveled EG7 or EL4 (E/T = 40) for 4 h. Then, the cytotoxicity against EG7 and EL4 was measured by 51Cr-release assay.
c CD11c− CD8+ T cells and CD11c+ CD8+ T cells were isolated from spleens by FACS sorting at day 15. The gene expression levels were
measured by quantitative PCR. Error bars show ± SEM; n = 4 to 5 per group (a) and ± SD (b, c). Student’s t-test (a) and Kluskal-Wallis test
with Dunn’s multiple comparison test (b) were performed to analyze statistical significance. * p < 0.05. The results are one of the two
independent experiments
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Poly(I:C) therapy induces CD11c+ CD8+ T cells in the
WT1-expressing tumor-bearing model
We next assessed the correlation between Poly(I:C)
efficacy and CD11c+ CD8+ T cell proliferation in
WT1-C1498, a WT1-expressing leukemia cell line de-
rived from the C57BL/6 mouse strain that is known
to be sensitive to CTL-mediated cytotoxicity [12].
The Wilms’ tumor gene, WT1, is expressed in several
human hematological malignancies and solid tumors
[22]. The WT1 protein has immunogenicity and
hence the potential to induce T cell activation [22].
We implanted WT1-C1498 cells into mice and sub-
cutaneously injected PBS or Poly(I:C) to the mice at
days 5 and 12 after tumor cell implantation. The
Poly(I:C) treatment lead to retardation of tumor
growth (Fig. 6a). In this model, WT1 protein was not
added to Poly(I:C), and WT1-specific CD8+ T cells
was only subtly induced; the Poly(I:C)-induced
(See figure on previous page.)
Fig. 3 CD11c expression is correlated with activation of tumor-infiltrating CD8+ T cells. a EG7 tumor bearing mice were treated with OVA or OVA +
Poly(I:C) at day 9. Six days later, tumors were harvested and the proportions of OVA-specific CD8+ T cells and CD11c+ CD8+ T cells were evaluated on
flow cytometer. b CD11c expression level on intratumor CD8+ T cells was evaluated on flow cytometer. Gating strategy is shown in the left panels,
and the CD11c expression levels on CD11c+ CD8+ T cells are shown in the right panel. c The proportions of OVA-specific populations on intratumor
CD11c− , CD11clo-mid and CD11chi CD8+ T cells were evaluated on flow cytometer. Gating strategy is shown in the left panel. Error bars show ± SEM;
n = 5 per group. Student’s t-test was performed to analyze statistical significance. * p < 0.05(a-c). d-e CD11c− , CD11clo-mid and CD11chi CD8+ T cells (d)
or OVA + Poly(I:C)-stimulated OVA-tetramer+ CD11c− and CD11c+ CD8+ T cells (e) were isolated from tumor tissues by FACS sorting at day 15. The
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Fig. 4 Antigen-specific cell proliferation correlates with CD11c expression in CD8+ T cells. a CD11c+ DCs were isolated from spleens of wild-type
mice and incubated with OVA in the presence or absence of Poly(I:C) for 4 h, and then co-cultured with CFSE-labeled OT-1 T cells. After 60 h,
antigen-specific proliferation was evaluated by diminution of CFSE with reference to cells gated. b The cycles of cell division and levels of CD11c+
OT-1 T cells are shown (the left and the middle panel). Division times and CD11c+ levels are analyzed with samples in panel A (the right panel).
Error bars show ± SEM. Student’s t-test was performed to analyze statistical significance. * p < 0.05. The results are the representatives of three
independent experiments
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increase in WT1-tetramer+ CD8+ T cells was below
the detection limit in spleen and tumor tissue
(Fig. 6b). However, the proportion of CD62L-negative
CD8+ T cells was increased following Poly(I:C) treat-
ment (Fig. 6b). This result indicates that activation of
CD8+ T cells is induced by Poly(I:C) monotherapy in
WT1-expressing tumors.
In this context, the proportion of CD11c+ CD8+ T cells
was also increased following Poly(I:C) administration
(Fig. 6b). The intratumor CD11c+ CD8+ T cells showed
higher cytotoxic genes expression than CD11c− CD8+ T
cells in PBS-control mice. These genes expression in
CD11c+ CD8+ T cells were increased more by Poly(I:C)
treatment as in EG7-bearing mice (Additional file 6:
Figure S5). Although Poly(I:C)-treatment induced tumor
growth retardation, the degree of the growth inhibitio-
nappeared to be different among individual mice. (left in
Fig. 6c). Further analysis revealed that the expansion of
CD11c+ CD8+ T cells was minimal in the former, while
robustly induced in the latter (right in Fig. 6c). Anyhow,
CD11c+ CD8+ T cells proliferate in tumor in response to
Poly(I:C) irrespective of tumor types.
Antigen immunization induces CD11c+ CD8+ T cell
expansion in human PBMCs
Finally, we tested whether CD11c+ CD8+ T cells prolifer-
ate in a human in vitro system. PBMCs were isolated
from four healthy donors and immunized with CMV
pp65 protein, in the presence or absence of Poly(I:C)
stimulation. After more than 8 days incubation, the
proportions of CMV-tetramer+ and CD11c+ CD8+ T
cells were analyzed (Fig. 7a). Regarding Donor-1-derived
PBMCs, CMV-tetramer+ CD8+ T cells were barely de-
tectable in Ag-free conditions and approximately 4 % of
CD8+ T cells expressed CD11c (left panels in Fig. 7b).
Under Ag-positive, Poly(I:C)-free conditions, CMV-
tetramer+ CD8+ T cells increased slightly and the per-
centage of CD11c+ cells increased to more than 6 %
(middle panels in Fig. 7b). When Poly(I:C) stimulation
was accompanied by Ag immunization, the expansion of
CMV-tetramer+ CD8+ T cells was induced more potently
and CD11c+ cells reached around 7.5 % (right panels in
Fig. 7b). In these Ag-positive situations, CD11c+
population contained more Ag-specific CD8+ T cells
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Fig. 5 Poly(I:C) increases CD11c+ CD8+ T cells independent of TICAM-1 and MAVS. KO mice were challenged with EG7 cells, and treated with
OVA with or without Poly(I:C) at day 9. Six days after OVA administration, spleens were harvested and the proportions of OVA-specific CD8+ T cells
and CD11c+ CD8+ T cells were evaluated on flow cytometer. Error bars show ± SEM; n = 2 to 3 per group
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ac
b
Fig. 6 Poly(I:C) therapy induces the expansion of CD11c+ CD8+ T cells in a WT1 tumor model. a Wild-type mice challenged with WT1-
C1498 tumor cells were treated with PBS or Poly(I:C) around tumor at day 5 and 12 after implantation. Tumor volume was measured
every 2 to 3 days. b At day 14, spleen and tumor were harvested and the proportions of WT1-specific CD8+ T cells, CD11c+ CD8+ T cells
and CD62L− CD8+ T cells were evaluated on flow cytometer. c The representative mice were selected from the PBS and Poly(I:C) group.
Tumor growth and the proportions of CD11c+ CD8+ T cells in spleen and tumor are shown. In the left panel, diamond indicates PBS-
treated control. triangle indicates Poly(I:C) low-responding mice. Circle indicates Poly(I:C) high-responding ones. Error bars show ± SEM;
n = 3 to 4 per group. Student’s t-test was performed to analyze statistical significance. * p < 0.05. The results are one of the two
independent experiments
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other donors, CMV-tetramer+ CD8+ T cells and CD11c+
CD8+ T cells were increased with Ag-only stimulation
(Additional file 7: Figure S6), which is consistent with the
result of Donor-1. Yet no additive increase was observed
by Poly(I:C) in this setting (data not shown). Upon
Ag + Poly(I:C)-stimulation in PBMC samples, the dy-
namics of tetramer+ CD8+ T cells and CD11c+ CD8+
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Fig. 7 CD11c+ CD8+ T cells expand in response to Ag immunization in human PBMCs. Human PBMCs isolated from donor-1 were treated with
CMV pp65 protein in the presence or absence of Poly(I:C). Negative control was a sample without Ag and Poly(I:C). Eight days after the treatment, the
proportions of CMV pp65 tetramer+ CD8+ T cells and CD11c+ CD8+ T cells were evaluated on flow cytometer. a The gating strategy is shown. Samples
were labeled with 7AAD, α-CD8 Ab, α-CD3 Ab or isotype of α-CD11c Ab without tetramer staining. b Upper panels show the percentage of
pp65 tetramer+ cells in CD8+ T cells. Lower panels show the percentage of CD11c+ cells in CD8+ T cells. c The percentage of pp65 tetramer+ cells in
CD11c negative- and CD11c positive-CD8+ T cells are shown
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of the in vitro assay for Poly(I:C) function in some
human samples. We would say, at least CD11c+ CD8+
T cells are increased with Ag stimulation and the levels
clearly correlate with those of Ag-specific CD8+ T cells in
human immune cells, partly as per the mouse models.
Discussion
In the present study of anti-tumor vaccine therapy, we
found that CD8+ T cells primed by DCs express the
CD11c molecule, which parallels the intensity of the
proliferation signal in the CD8+ T cells. We also demon-
strated that primed CD11c+ CD8+ T cells exert an ef-
fector phenotype and contribute to tumor regression in
mouse; in two tumor-implant models, EG7(OVA) and
C1498(WT1), CD11c+ CD8+ T cell expansion is feasible
accompanied with potent therapeutic efficacy. CD11c re-
flects an activation state of CD8+ T cells with killing ac-
tivity in inflammatory microenvironment, encompassing
infection and tumor.
CD11c is a subunit of beta2 integrin, namely p150,95
or CR4 [23] and selectively expressed on myeloid cells,
in particular DCs [24]. The molecule is also expressed
on a minor population of CD8+ T cells in spleen, lymph
node, thymus, liver and bone marrow in naïve mouse
models [25, 26]. CD11c+ CD8+ T cells also exist in the
intestines where the proportion of CD11c+ cells is higher
than other organs [25, 27]. When mice are infected with
pathogenic microbes such as bacteria, protozoa and vi-
ruses, the CD11c+ T cell moiety is dramatically ex-
panded in lymphoid tissues, blood and infected lesions
[14, 28, 29]. In infection models, the CD11c+ T cells
have been shown to exhibit a short-lived effecter pheno-
type, with high killing activity and IFN-γ-producing abil-
ity [13, 14, 28, 29]. In a Listeria monocytogenes-infected
mouse model, the killing ability of CD11c+ CD8+ T cells
is reduced by the blocking of CD11c [13], which illus-
trates that CD11c is not only a phenotypic marker of ac-
tivated CD8+ T cells, but also plays an important role in
mediating their cytotoxic effect. Since CD11c is a recep-
tor for C3bi [23, 30], it enhances interaction with C3bi-
coated particle [31]. Tumor cells tend to be labeled with
C3bi in inflammatory environment, which might pro-
mote CTL-mediated tumor cell clearance [32].
Based on earlier reports on a increase of the CD11c+
CD8+ T population in infections [13, 14, 28, 29], there
might be two possibilities in expansion of CD11c popula-
tion in CD8+ T cells: inducible of CD11c in popular CD8+
T cells or proliferation of a unique CD8+ T subset that es-
sentially expresses CD11c. In our in vivo setting with
tumor-infiltrated CD8+ T cells, the CD11c level in CD8+
T cells is up-regulated in accordance with number of the
CD11c+ CD8+ T cells in response to Poly(I:C). Thus, the
both mechanisms appear to participate in abundance of
CD11c-positive cells in CD8+ T cell population in tumor
when the mice are stimulated with Poly(I:C). In a resting
state of mouse, there exists a minor population of CD11c+
CD8+ T cells, which needs to be further analyzed.
We previously showed that the single administration
of OVA failed to induce OVA-specific CD8+ T cell pro-
liferation in spleen [3]. However, a small number of
CD11c+ CD8+ T cells exist in both the tumor-bearing
and non-tumor-bearing models, even in the absence of
Poly(I:C) stimulation (Fig. 1c and Additional file 2:
Figure S1a). The constitutive CD11c+ T cells in spleen
demonstrate a similar gene expression profile as effector
CD8+ T cells (Fig. 2c). Only a few CD8+ T cells express-
ing CD11c would remain active in a non-stimulated
state. The homeostatic activation of CD11c+ CD8+ T
cells may include putative Ag-specific memory CD8+ T
cells recognizing tumor-associated or self-Ags. Although
these activated T cells are numerically and qualitatively
insufficient to induce tumor regression, the CD11c+
CD8+ T cell population expands to enhance the effector
function once Poly(I:C) stimulation primes Ag-specific
CD8+ T cells in mice.
In contrast to the activation of CD8+ T cells [13, 28],
several papers have focused on the suppressive functions
of the CD11c+ CD8+ T cells. The CD11chi population is
able to kill activated CD4+ T cells in Listeria-infected
mice [13]. In 4-1BB-stimulated rheumatoid arthritis or
autoimmune uveoretinitis mouse models, IFN-γ produced
from CD11c+ CD8+ T cells up-regulates. Indoleamine-
pyrrole 2,3-dioxygenase (IDO) enzyme in DCs and macro-
phages, which ameliorates inflammatory-mediated tissue
damage [33, 34]. Thus, some of the immunosuppressive
functions of CD11c+ CD8+ T cells occur in tumor second-
ary to their strong effector function, to prevent excessive
or abrupt tumor destruction.
Regarding intratumor CD11c+ CD8+ T cells, their
number and phenotype reflect both the migration and
effector phases. The proportion of the CD11c+ popula-
tion in CD8+ T cells is much higher in tumor than in
spleen or DLN (Figs. 1c, d and 3a), with over 60 % of
the intratumor CD8+ T cells expressing the CD11c mol-
ecule. The same distribution is observed in B16-F10
melanoma-bearing mouse models given the agonistic
anti-4-1BB monoclonal antibody-monotherapy or com-
bination therapy with anti-CD4 antibody [15, 35]. The
primed CD8+ T cells acquire the ability to migrate, pre-
sumably through the up-regulation of the chemokine re-
ceptor Cxcr3 in spleen; thus these primed CD11c+ CD8+
T cells may preferentially accumulate in tumor bed.
When CD8+ T cells are activated, the level of PD-1 ex-
pression is up-regulated via T cell receptor signaling
[36]. These activated CTLs may exhibit high tumoricidal
activity but exhaust easily in a high PD-L1 tumor micro-
environment. Hence, the number and activation state of
CD8+ T cells infiltrating into the tumor would be in
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temporally parallel. In our EG7-bearing model, intratumor
CD11c+ cells showed similar gene expression profiles to
splenic CD11c+ CD8+ T cells (Fig. 3d, e) with the proper-
ties of active CTL on the way to tumor regression. CD11c
CD8+ T cells may be increased as an activation marker in
human PBMC samples stimulated with Ag. Therefore, as
a prediction marker for therapeutic efficacy in patients,
the number and level of CD11c expression in CD11c+
CD8+ T cells in blood would predict the quality of intratu-
mor CTLs in cancer patients having immunotherapy.
In clinical human cancer immunotherapy, short
peptides containing epitopes are found apparently in-
effective [37, 38]. The main problems of short pep-
tides therapy include low immunogenicity and HLA-
restriction [39]. Whole tumor-Ag protein is difficult to
provide because of the difficulty in synthesizing high-
grade protein [18]. Poly(I:C)-monotherapy is more prac-
tical than treatment with TAA+ Poly(I:C) in patients with
cancer having unidentified TAA as per BCG-CWS thrapy
[40, 41]. However, the Poly(I:C)-monotherapy appears in-
sufficient to support the potent priming of Ag-specific
CD8+ T cells compared with Ag + Poly(I:C) therapy,
as shown in C1498 (WT1) versus EG7 (OVA)-bearing
mouse models [2, 3, 42]. In addition, there appears to
be an individual-to-individual difference in the re-
sponse to Poly(I:C) treatment (Fig. 7 and Additional
file 7: Figure S6). Expansion of CD11c+ CD8+ T cells
should be judged based on the reflection of tumor re-
gression and therapeutic efficacy.
Finally, we used an ex vivo HLA CMV-tetramer assay
for testing expansion of Ag-specific CD11c+ T cells in
human PBMC samples. Results showed an obvious expan-
sion of CD11c+ population following the immunization by
CMV Ag in Poly(I:C)-free conditions (Fig. 7). However,
this tendency of tetramer+ and CD11c+ CD8+ T cells was
poorly reproduced in some other donors in response
to Ag + Poly(I:C)-stimulation. Since Poly(I:C) induces
activation-induced or necroptotic cell death in various
types of cells [43, 44], the Poly(I:C) dose may have critic-
ally affected the PBMC conditions in this artificial assay
system [45]. Yet, these human PBMC studies suggest that
Ag-stimulation impacts the link between activation and
increase of CD11c+ CD8+ T cells as in the mouse models.
Conclusions
In conclusion, CD11c+ CD8+ T cell population cru-
cially expands in anti-tumor immunotherapy, and reflects
proliferation of tumor antigen-specific CTL in mouse
tumor-implant models. Expansion of CD11c+ CD8+ T cell
population reveals a possible marker for successful im-
munotherapy in mouse, and possibly in human clinical
tests. It would be more suitable and convenient to evaluate
overall CD8+ T expansion and CD11c marker than to em-
ploy a tetramer assay with unidentified Ags, but we need to
check the period when this parallelism is observed. The ex-
pansion of CD11c+ CD8+ T cells in response to vaccine and
adjuvant would be a simple and practical marker for the
adaptability of immunotherapy to cancer patients.
Additional files
Additional file 1: Table S1. Primer sequences used for real-time RT-PCR.
(DOCX 20.7 kb)
Additional file 2: Figure S1. CD11c+ CD8+ T cells show Ag + Poly(I:C)-
induced effector functions in non-tumor bearing mice. a-b OVA with or
without Poly(I:C) was s.c. injected to tumor-unloading mice. Seven days later,
spleens and DLN were harvested and the proportions of OVA-specific CD8+ T
cells, CD11c+ CD8+ T cells (a) and IFN-g+ CD8+ T cells (b) were evaluated by
flow cytometer. Error bars show ± SEM; n = 5 per group. Student’s t-test was
performed for statistical significance. * p < 0.05 (a, b). c CD11c- CD8+ T cells
and CD11c+ CD8+ T cells were isolated from spleens by flow cytometer
sorting at day 7. Isolated cells were cocultured with 51Cr-labeled EG7 or EL4
(E/T = 20) for 4 hours. Then, the cytotoxicity against EG7 and EL4 was
measured by 51Cr-release assay. Error bars show ± SEM. (DOCX 128 kb)
Additional file 3: Figure S2. Gene expression profile of CD11c+ CD8+ T
cells. a-b EG7 tumor-bearing mice were treated with OVA or OVA + Poly(I:C)
at day 9. Six days later, spleens were harvested and the proportions of CD62L-,
PD-1+, KLRG1+ /CD127- and CD103+ of the CD8+ T cells (a) and TNF-a+ and
IL-2+ of the CD8+ T cells (b) were evaluated by flow cytometer. c CD11c- CD8+
and CD11c+ CD8+ T cells were isolated from spleens and tumors by FACS
sorting at day 15. The gene expression levels were measured by quantitative
PCR. Error bars show ± SEM; n = 3 to 9 per group (a, b) and ± SD (c).
Student’s t-test was performed for statistical significance. * p < 0.05. The results
are one of the two independent experiments. (DOCX 214 kb)
Additional file 4: Figure S3. Tumor-infiltrating CD11c+ CD8+ T cells
disappear immediately before the complete tumor regression. a EG7
tumor-bearing mice were administered with OVA and Poly(I:C) around
tumor at day 5 after tumor implantation. Tumor volume was measured
every 2 to 3 days. Tumors with mild (+) and rapid (++) regression profiles
(≥ 200 mm3 at day 12 vs. ≤ 200 mm3 at day 12) were used in this study.
b 7 days after OVA treatment (on day 12), the proportions of intratumor
OVA-specific CD8+ T cells and CD11c+ CD8+ T cells were evaluated on
flow cytometer. The results are the representatives of three independent
experiments. (DOCX 93 kb)
Additional file 5: Figure S4. CD11c+ CD8+ T cells are induced by Ag
and TLR2 adjuvant therapy. a EG7 tumorbearing mice were treated with OVA
or OVA + MALP2s at day 5 and 12 after tumor implantation. Tumor volume
was measured every 2 to 3 days. b DLN and tumors were harvested at day
18 and the proportions of OVA-specific CD8+ T cells and CD11c+ CD8+ T
cells were evaluated on flow cytometer. Error bars show ± SEM; n = 3 to 5
per group. Student’s t-test was performed to analyze statistical significance.
* p < 0.05. (DOCX 107 kb)
Additional file 6: Figure S5. Intratumor CD11c+ CD8+ T cells show
high expression of the cytotoxic genes in mice bearing WT1-C1498 tumor.
WT1-C1498 cells were implanted to wild-type mice, and PBS or Poly(I:C) was
administered around the tumor at day 5 after tumor implantation. CD11c-
and CD11c+ CD8+ T cells were isolated from tumor tissues by FACS sorting
on day 12. The gene expression levels were measured by quantitative PCR.
Error bars show ± SD. (DOCX 64.1 kb)
Additional file 7: Figure S6. Expansion of CD11c+ CD8+ T cells in CMV
Ag-treated PBMCs isolated from additional donors. PBMCs isolated from three
donors were incubated with or without CMV pp65 protein as in Figure 7 in
Poly(I:C)-free conditions. PBMCs from donor-2 and donor-3 were incubated
for 10 days. PBMCs from donor-4 were incubated for 8 days. Then, the
proportions of CMV pp65 tetramer+ CD8+ T cells (upper panels) and CD11c+
CD8+ T cells (lower panels) were evaluated on flow cytometer. (DOCX 174 kb)
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